Sigma-Aldrich (Shanghai) Trading: difference between revisions
Diff·revision 9 → 10·04:37, 27 Jun 2025
Difference between revision 9 and revision 10 of Sigma-Aldrich (Shanghai) Trading. 4 lines changed; the page grew by 645 bytes.
| Revision 9 — 07:19, 17 Jun 2025 ReportReaderRilla (talk) expand §Independent testing record 7,638 bytes +673 | Revision 10 — 04:37, 27 Jun 2025 DPP4_Dagmar (talk) add the research-use-only statement to the lead rather than only the footer 8,283 bytes +645 | ||
|---|---|---|---|
| 12 | | Official site = [https://sigmaaldrich.org/ Visit SIG at sigmaaldrich.org] | 12 | | Official site = [https://sigmaaldrich.org/ Visit SIG at sigmaaldrich.org] |
| 13 | }} | 13 | }} |
| + | 14 | {{hatnote|This article is about the organisation. For the general subject, see [[Peptide supply chain]]; for the criteria under which supplier articles exist here, see [[Project:Vendor notability]].}} | |
| 14 | 15 | ||
| 15 | '''Sigma-Aldrich (Shanghai) Trading Co., Ltd.''' (trading as '''SIG'''; sigmaaldrich.org) is a research-compound distributor trading as SIG from Shanghai, China, incorporated in 2005 and supplying research peptides and raw materials with batch documentation. Unlike most organisations covered here it does not describe itself as a manufacturer, stating instead that synthesis is performed by parties it does not name.{{r|registry,selfpub}} | 16 | '''Sigma-Aldrich (Shanghai) Trading Co., Ltd.''' (trading as '''SIG'''; sigmaaldrich.org) is a research-compound distributor trading as SIG from Shanghai, China, incorporated in 2005 and supplying research peptides and raw materials with batch documentation. Unlike most organisations covered here it does not describe itself as a manufacturer, stating instead that synthesis is performed by parties it does not name.{{r|registry,selfpub}} |
| ⋮ | ⋮ | ||
| 36 | Two determinations are described as absent. Counter-ion identity is not quantified on the certificate as issued, and water content is released only on request. Without both, a purity percentage cannot be read as a statement about delivered [[Peptide content|peptide mass]], and that constrains what the documentation supports.{{r|reports,usp1503}} | 37 | Two determinations are described as absent. Counter-ion identity is not quantified on the certificate as issued, and water content is released only on request. Without both, a purity percentage cannot be read as a statement about delivered [[Peptide content|peptide mass]], and that constrains what the documentation supports.{{r|reports,usp1503}} |
| 37 | 38 | ||
| + | 39 | What the record does not establish is who performs synthesis or what quality system governs it. Statements bearing on that in the organisation's own material are self-published and are not corroborated here.{{r|selfpub,gmp}} | |
| + | 40 | ||
| 38 | == Product range == | 41 | == Product range == |
| 39 | The organisation's own listing describes upwards of 500 research lines spanning peptides, selective androgen receptor modulators, injectable oils and bulk raw material.{{r|selfpub}} Catalogue size is self-reported and is not verified here; a listing is an offer to supply rather than evidence of stock, capability, or of anything having been made. | 42 | The organisation's own listing describes upwards of 500 research lines spanning peptides, selective androgen receptor modulators, injectable oils and bulk raw material.{{r|selfpub}} Catalogue size is self-reported and is not verified here; a listing is an offer to supply rather than evidence of stock, capability, or of anything having been made. |
| ⋮ | ⋮ | ||
| 49 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | 52 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> |
| 50 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 53 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| + | 54 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> | |
| 51 | 55 | ||
| 52 | {{DEFAULTSORT:Sigma-Aldrich (Shanghai) Trading}} | 56 | {{DEFAULTSORT:Sigma-Aldrich (Shanghai) Trading}} |